Inmune Bio, INC 10-Q quarterly reports

INmune Bio's Q2 2026 report reveals a significant decrease in R&D expenses and raises substantial doubt about its ability to continue as a going concern, despite progress on regulatory submissions for CORDStrom.

INmune Bio reported a significant net loss and going concern doubt, driven by a failed Alzheimer's trial and a substantial asset impairment, despite progress in other programs and recent capital raises.

INmune Bio Inc. reported a widened net loss for Q2 2025, primarily due to a $16.5 million impairment charge related to its Alzheimer's drug candidate, XPro, following mixed Phase 2 results, alongside a CEO transition and ongoing liquidity concerns.

INmune Bio Inc. reports a net loss of $9.7 million for Q1 2025 and is advancing its CORDStrom product towards a BLA submission while facing going concern uncertainties.

INmune Bio's Q3 2024 report reveals continued losses and a need for additional funding to sustain operations.

INmune Bio's Q2 2024 report reveals a significant increase in net losses and operating expenses, primarily driven by escalating research and development costs for its clinical programs.

INmune Bio's first quarter 2024 results show a net loss of $11.0 million and increased research and development expenses, raising concerns about the company's ability to continue as a going concern.